Overview

Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study seeks to evaluate the efficacy, side effect profile and acceptability of a medical abortion regimen with mifepristone and two doses of 800 mcg misoprostol buccally at 71-77 and 78-84 days of gestation to further expand the evidence base for the most effective regimens in the late first trimester of pregnancy.
Phase:
Phase 4
Details
Lead Sponsor:
Gynuity Health Projects
Collaborator:
Society of Family Planning
Treatments:
Mifepristone
Misoprostol